Hematology & Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Renal Cell Carcinoma 65%
3. Therapeutics 45%
4. Non-Small Cell Lung Carcinoma 43%
5. Diphtheria Toxin 38%
6. Survival 36%
7. Mutation 34%
8. Acute Myeloid Leukemia 33%
9. Immunotoxins 32%
10. Lung Neoplasms 30%
11. palmitoyl-protein thioesterase 30%
12. Drug Therapy 30%
13. Proteins 29%
14. Breast Neoplasms 27%
15. Glioblastoma 26%
16. Ricin 25%
17. Genes 22%
18. Brain Neoplasms 21%
19. Immunotherapy 21%
20. Neoplasm Metastasis 20%
21. Nivolumab 20%
22. Radiotherapy 19%
23. Melanoma 18%
24. Safety 18%
25. Clinical Trials 18%
26. Prostatic Neoplasms 18%
27. Progression-Free Survival 18%
28. Leukemia 17%
29. Pharmaceutical Preparations 17%
30. Ceroid lipofuscinosis, neuronal 1, infantile 17%
31. anthrax toxin 16%
32. Glioma 16%
33. Cell Line 16%
34. Growth 16%
35. Bone Marrow 15%
36. Huntingtin Protein 15%
37. Enzymes 14%
38. Neuronal Ceroid-Lipofuscinoses 14%
39. Granulocyte-Macrophage Colony-Stimulating Factor 14%
40. ErbB Receptors 14%
41. T-Lymphocytes 13%
42. Brain 13%
43. Colorectal Neoplasms 13%
44. Stem Cells 13%
45. Isocitrate Dehydrogenase 12%
46. Kidney Neoplasms 12%
47. Liver 12%
48. Sickle Cell Anemia 12%
49. Monoclonal Antibodies 12%
50. Recurrence 12%
51. alpha-hydroxyglutarate 12%
52. In Vitro Techniques 12%
53. Antibodies 12%
54. Blood Platelets 11%
55. Graft vs Host Disease 11%
56. Thrombosis 11%
57. Heterografts 11%
58. Transplants 11%
59. Interleukin-3 11%
60. Sunitinib 11%
61. Protein-Tyrosine Kinases 10%
62. Adenocarcinoma 10%
63. DNA 10%
64. Population 10%
65. Pharmacokinetics 10%
66. Blood-Brain Barrier 10%
67. Biomarkers 10%
68. Carcinogenesis 10%
69. Apoptosis 10%
70. Lymphoma 10%
71. Bone Marrow Transplantation 10%
72. Bevacizumab 10%
73. Vitamin B 12 9%
74. Confidence Intervals 9%
75. Vascular Endothelial Growth Factor A 9%
76. Radiosurgery 9%
77. Interleukin-3 Receptors 9%
78. Pancreatic Neoplasms 9%
79. Small Cell Lung Carcinoma 9%
80. Cisplatin 9%
81. Fluorouracil 9%
82. Kidney 9%
83. Barrett Esophagus 9%
84. Interleukin-2 9%
85. Tissue Donors 9%
86. Thrombocytopenia 9%
87. Hematologic Neoplasms 9%
88. Lung 8%
89. Multiple Myeloma 8%
90. Docetaxel 8%
91. Ipilimumab 8%
92. Peptides 8%
93. Radiation 8%
94. Maximum Tolerated Dose 8%
95. Erlotinib Hydrochloride 8%
96. Ligands 8%
97. Serum 7%
98. Everolimus 7%
99. Thrombotic Thrombocytopenic Purpura 7%
100. B-Cell Chronic Lymphocytic Leukemia 7%